Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
DRD2 1813 FLUPHENAZINE ENANTHATE CHEMBL1200951 antagonist ChemblInteractions
DRD2 1813 LOXAPINE CHEMBL831 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 8101879, 11752352, 9342550, 8665533, 15694653, 6239298, 9570468
DRD2 1813 ROPINIROLE HYDROCHLORIDE CHEMBL1200411 agonist ChemblInteractions
DRD2 1813 PROCHLORPERAZINE MALEATE CHEMBL1200587 antagonist ChemblInteractions
DRD2 1813 CABERGOLINE CHEMBL1201087 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 15341508, 11436517, 11752352, 12008749, 12464354, 8951172, 18303487, 12721865
DRD2 1813 APOMORPHINE CHEMBL53 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 10641988, 18691132, 11212866, 11752352, 11343576, 10494453, 11215397, 11692072
DRD2 1813 RISPERIDONE CHEMBL85 antagonist DrugBank, GuideToPharmacologyInteractions, TTD, ChemblInteractions, TEND, TdgClinicalTrial 11132243, 17059881, 11752352, 15907153, 16513859, 15140279, 16730699
DRD2 1813 PERPHENAZINE CHEMBL567 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 7828655, 11752352, 11873706, 2573104, 15007534, 7508675
DRD2 1813 CARPHENAZINE CHEMBL1201328 antagonist TdgClinicalTrial, TEND, DrugBank, TTD 4887393, 11752352, 4861216, 4889058
DRD2 1813 ERGOLOID MESYLATES CHEMBL2311030 agonist, antagonist ChemblInteractions, DrugBank 2869188
DRD2 1813 ACETOPHENAZINE CHEMBL1085 antagonist TdgClinicalTrial, TEND, DrugBank, TTD 6147851, 17139284, 17016423, 11873706, 11752352
DRD2 1813 PIMOZIDE CHEMBL1423 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 11752352, 12828573, 11873706, 2378927, 8082693, 8301582, 10503726, 7855217
DRD2 1813 ARIPIPRAZOLE CHEMBL1112 partial agonist, agonist, antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 16981227, 16925992, 16366516, 11752352, 17501690, 9083792
DRD2 1813 CHEMBL2165119 CHEMBL2165119 agonist GuideToPharmacologyInteractions
DRD2 1813 CHEMBL285755 CHEMBL285755 agonist GuideToPharmacologyInteractions
DRD2 1813 BROMOCRIPTINE CHEMBL493 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
DRD2 1813 PERGOLIDE CHEMBL531 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
DRD2 1813 SUMANIROLE CHEMBL419792 agonist GuideToPharmacologyInteractions, TTD
DRD2 1813 TERGURIDE CHEMBL73151 agonist, antagonist GuideToPharmacologyInteractions
DRD2 1813 ETICLOPRIDE CHEMBL8946 antagonist GuideToPharmacologyInteractions
DRD2 1813 CHEMBL1627081 CHEMBL1627081 antagonist GuideToPharmacologyInteractions
DRD2 1813 PEROSPIRONE CHEMBL1472975 antagonist GuideToPharmacologyInteractions
DRD2 1813 QUETIAPINE CHEMBL716 agonist, antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
DRD2 1813 RACLOPRIDE CHEMBL8809 antagonist GuideToPharmacologyInteractions
DRD2 1813 STEPHOLIDINE CHEMBL487387 antagonist GuideToPharmacologyInteractions
DRD2 1813 CHEMBL196677 CHEMBL196677 antagonist GuideToPharmacologyInteractions
DRD2 1813 [3H]NEMONAPRIDE CHEMBL2261102 antagonist GuideToPharmacologyInteractions
DRD2 1813 ZOTEPINE CHEMBL285802 antagonist GuideToPharmacologyInteractions
DRD2 1813 CHLORPROTHIXENE CHEMBL908 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 11752352, 1830565, 8101879, 19091563
DRD2 1813 ALIZAPRIDE CHEMBL290194 antagonist DrugBank 10075867, 2943980, 7865862, 8103596
DRD2 1813 THIOPROPERAZINE CHEMBL609109 antagonist DrugBank 11752352, 11873706, 15694263, 20643630, 16867246, 11103886
DRD2 1813 PARDOPRUNOX HYDROCHLORIDE CHEMBL2105649 DrugBank
DRD2 1813 OLANZAPINE PAMOATE CHEMBL1201741 antagonist ChemblInteractions
DRD2 1813 Ordopidine CHEMBL3545010 modulator ChemblInteractions
DRD2 1813 HALOPERIDOL LACTATE CHEMBL2096643 inverse agonist ChemblInteractions
DRD2 1813 TRIFLUOPERAZINE HYDROCHLORIDE CHEMBL1710 antagonist ChemblInteractions
DRD2 1813 TRIFLUPROMAZINE HYDROCHLORIDE CHEMBL1201102 antagonist ChemblInteractions
DRD2 1813 LONAPALENE CHEMBL36648 TdgClinicalTrial
DRD2 1813 CHEMBL239767 CHEMBL239767 antagonist TTD
DRD2 1813 E-FLUPENTIXOL CHEMBL42055 TdgClinicalTrial, TEND
DRD2 1813 DEXPRAMIPEXOLE CHEMBL249420 TdgClinicalTrial
DRD2 1813 ABAPERIDONE (CHEMBL151475) CHEMBL151475 antagonist TTD
DRD2 1813 BUPROPION CHEMBL894 PharmGKB
DRD2 1813 CHEMBL221692 CHEMBL221692 agonist TTD
DRD2 1813 CHEMBL25074 CHEMBL25074 binder TTD
DRD2 1813 SIBENADET CHEMBL82663 agonist TTD
DRD2 1813 THIETHYLPERAZINE MALEATE CHEMBL1200856 antagonist ChemblInteractions
DRD2 1813 OLANZAPINE CHEMBL715 agonist, antagonist PharmGKB, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 17848919, 11752352, 16513877, 17092971, 17316700, 16730699, 14575800, 17067304
DRD2 1813 AMOXAPINE CHEMBL1113 antagonist ChemblInteractions, DrugBank 1966571, 11180191
DRD2 1813 THIETHYLPERAZINE CHEMBL1378 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423, 15469457
DRD2 1813 CINNARIZINE CHEMBL43064 DrugBank 7714010, 9014432
DRD2 1813 PROPIOMAZINE CHEMBL1201210 antagonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
DRD2 1813 MINAPRINE CHEMBL278819 agonist TdgClinicalTrial, TEND, DrugBank 17139284, 17016423
DRD2 1813 AMANTADINE HYDROCHLORIDE CHEMBL1569 agonist DrugBank 10443547, 8566141, 9098680, 9806328
DRD2 1813 BENZQUINAMIDE CHEMBL1201250 agonist GuideToPharmacologyInteractions
DRD2 1813 DOPAMINE CHEMBL59 agonist GuideToPharmacologyInteractions, TTD
DRD2 1813 PRAMIPEXOLE CHEMBL301265 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
DRD2 1813 ROXINDOLE CHEMBL431367 agonist, antagonist GuideToPharmacologyInteractions
DRD2 1813 AMISULPRIDE CHEMBL243712 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 16696579, 11873706, 12404702
DRD2 1813 BLONANSERIN CHEMBL178803 antagonist GuideToPharmacologyInteractions, TTD
DRD2 1813 NAFADOTRIDE CHEMBL286252 antagonist GuideToPharmacologyInteractions
DRD2 1813 YOHIMBINE CHEMBL15245 antagonist DrugBank 10611634
DRD2 1813 ZUCLOPENTHIXOL CHEMBL87385 antagonist TdgClinicalTrial, TEND, DrugBank, TTD 1822319, 11752352, 17535043, 8748043
DRD2 1813 LURASIDONE CHEMBL1237021 antagonist TdgClinicalTrial, TEND, DrugBank 23545936
DRD2 1813 CHEMBL131495 CHEMBL131495 antagonist TTD
DRD2 1813 MOLINDONE CHEMBL460 binder TdgClinicalTrial, TEND, TTD
DRD2 1813 PROMAZINE HYDROCHLORIDE CHEMBL1200469 antagonist ChemblInteractions
DRD2 1813 HALOPERIDOL DECANOATE CHEMBL1200986 inverse agonist ChemblInteractions
DRD2 1813 THIORIDAZINE HYDROCHLORIDE CHEMBL1200916 antagonist ChemblInteractions
DRD2 1813 APOMORPHINE HYDROCHLORIDE CHEMBL1616 agonist ChemblInteractions
DRD2 1813 ARIPIPRAZOLE LAUROXIL CHEMBL2219425 partial agonist ChemblInteractions
DRD2 1813 SB-773812 CHEMBL3545102 antagonist ChemblInteractions
DRD2 1813 LOXAPINE SUCCINATE CHEMBL1201155 antagonist ChemblInteractions
DRD2 1813 PALIPERIDONE PALMITATE CHEMBL1201732 antagonist ChemblInteractions
DRD2 1813 MESORIDAZINE BESYLATE CHEMBL1201052 antagonist ChemblInteractions
DRD2 1813 THIOTHIXENE HYDROCHLORIDE CHEMBL1200902 antagonist ChemblInteractions
DRD2 1813 QUINAGOLIDE (CHEMBL290962) CHEMBL290962 agonist TTD
DRD2 1813 METOCLOPRAMIDE CHEMBL86 antagonist TdgClinicalTrial, TEND, TTD
DRD2 1813 APLINDORE CHEMBL2110659 TdgClinicalTrial
DRD2 1813 DEXTROAMPHETAMINE CHEMBL612 agonist TTD
DRD2 1813 CAFFEINE CHEMBL113 PharmGKB
DRD2 1813 MELEVODOPA CHEMBL1328898 TdgClinicalTrial
DRD2 1813 NEMONAPRIDE CHEMBL20734 agonist PharmGKB, TTD
DRD2 1813 CARIPRAZINE HYDROCHLORIDE CHEMBL2024517 modulator ChemblInteractions
DRD2 1813 FLUPHENAZINE HYDROCHLORIDE CHEMBL1200792 antagonist ChemblInteractions
DRD2 1813 APLINDORE FUMARATE CHEMBL2104864 partial agonist ChemblInteractions
DRD2 1813 LURASIDONE HYDROCHLORIDE CHEMBL1615372 antagonist ChemblInteractions, TTD
DRD2 1813 Seridopidine CHEMBL3545388 modulator ChemblInteractions
DRD2 1813 SARIZOTAN HYDROCHLORIDE CHEMBL2146110 partial agonist ChemblInteractions
DRD2 1813 ZIPRASIDONE MESYLATE CHEMBL1200997 antagonist ChemblInteractions
DRD2 1813 LOXAPINE HYDROCHLORIDE CHEMBL1201060 antagonist ChemblInteractions
DRD2 1813 LEVOMEPROMAZINE CHEMBL1764 antagonist ChemblInteractions, DrugBank 2870716, 15701205, 10592235
DRD2 1813 SULPIRIDE CHEMBL26 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, TTD
DRD2 1813 DOMPERIDONE CHEMBL219916 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 11752352, 18970411, 1683559, 15894081, 12010185
DRD2 1813 ROPINIROLE CHEMBL589 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 10641988, 18691132, 11752352, 17573046, 10446316, 1683559
DRD2 1813 MIRTAZAPINE CHEMBL654 binder DrugBank 15771415, 12109911, 3419539
DRD2 1813 TRIFLUPROMAZINE CHEMBL570 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 17139284, 17016423
DRD2 1813 LISURIDE CHEMBL157138 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 11752352, 18691132
DRD2 1813 FLUPENTIXOL CHEMBL54661 antagonist GuideToPharmacologyInteractions, DrugBank, TTD 17111172, 1674528, 11752352, 11873706, 6149133, 8797192, 7498321
DRD2 1813 MESORIDAZINE CHEMBL1088 agonist, antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 11752352, 15357957, 16135699
DRD2 1813 VILAZODONE CHEMBL439849 agonist GuideToPharmacologyInteractions
DRD2 1813 CHEMBL2165126 CHEMBL2165126 agonist GuideToPharmacologyInteractions
DRD2 1813 CHEMBL2165138 CHEMBL2165138 agonist GuideToPharmacologyInteractions
DRD2 1813 CHEMBL97424 CHEMBL97424 agonist GuideToPharmacologyInteractions
DRD2 1813 QUINELORANE CHEMBL155731 agonist GuideToPharmacologyInteractions
DRD2 1813 QUINPIROLE CHEMBL240773 agonist GuideToPharmacologyInteractions
DRD2 1813 PIRIBEDIL (CHEMBL1371770) CHEMBL1371770 agonist GuideToPharmacologyInteractions
DRD2 1813 CHEMBL1255588 CHEMBL1255588 antagonist GuideToPharmacologyInteractions
DRD2 1813 CHLORPROMAZINE CHEMBL71 antagonist PharmGKB, GuideToPharmacologyInteractions, ChemblInteractions, TTD
DRD2 1813 FLUPHENAZINE CHEMBL726 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
DRD2 1813 ZIPRASIDONE CHEMBL708 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
DRD2 1813 PALIPERIDONE CHEMBL1621 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 12211096, 11132243, 11752352, 16513859, 7531353, 7524043, 16119512
DRD2 1813 FLUSPIRILENE CHEMBL46516 antagonist TdgClinicalTrial, TEND, DrugBank, TTD 8935801, 11752352, 17139284, 17016423, 11842444
DRD2 1813 TETRABENAZINE CHEMBL117785 inhibitor DrugBank
DRD2 1813 BRASOFENSINE CHEMBL2104184 DrugBank 17908924
DRD2 1813 ILOPERIDONE CHEMBL14376 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 12861482, 8997630
DRD2 1813 PIMAVANSERIN CHEMBL2111101 DrugBank
DRD2 1813 THIORIDAZINE CHEMBL479 antagonist TdgClinicalTrial, ChemblInteractions, TEND
DRD2 1813 PRAMIPEXOLE DIHYDROCHLORIDE CHEMBL542257 agonist ChemblInteractions
DRD2 1813 CARPHENAZINE MALEATE CHEMBL2358147 antagonist ChemblInteractions
DRD2 1813 ZIPRASIDONE HYDROCHLORIDE CHEMBL1712 antagonist ChemblInteractions
DRD2 1813 ASENAPINE MALEATE CHEMBL3544974 antagonist ChemblInteractions
DRD2 1813 TRIMIPRAMINE MALEATE CHEMBL1200948 antagonist ChemblInteractions
DRD2 1813 CHEMBL201839 CHEMBL201839 agonist TTD
DRD2 1813 METHAMPHETAMINE CHEMBL1201201 agonist TTD
DRD2 1813 CHEMBL2078915 CHEMBL2078915 antagonist TTD
DRD2 1813 CHEMBL430798 CHEMBL430798 antagonist TTD
DRD2 1813 NOMIFENSINE CHEMBL273575 antagonist TTD
DRD2 1813 ETILEVODOPA CHEMBL1823681 TdgClinicalTrial
DRD2 1813 CHEMBL165679 CHEMBL165679 antagonist TTD
DRD2 1813 CHEMBL1188853 CHEMBL1188853 antagonist TTD
DRD2 1813 THIETHYLPERAZINE MALATE CHEMBL1201074 antagonist ChemblInteractions
DRD2 1813 PERGOLIDE MESYLATE CHEMBL1275 agonist ChemblInteractions
DRD2 1813 OCAPERIDONE CHEMBL2104619 antagonist TTD
DRD2 1813 PRIDOPIDINE CHEMBL596802 modulator TdgClinicalTrial, ChemblInteractions
DRD2 1813 BENZQUINAMIDE HYDROCHLORIDE CHEMBL1200707 modulator ChemblInteractions
DRD2 1813 FLUPHENAZINE DECANOATE CHEMBL1200854 antagonist ChemblInteractions, TTD
DRD2 1813 CLOZAPINE CHEMBL42 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, NCI, TEND, DrugBank, TTD 12887421, 16040180, 15781964, 11752352, 12769622, 14575800, 15286066
DRD2 1813 REMOXIPRIDE CHEMBL22242 antagonist TdgClinicalTrial, TEND, DrugBank, TTD 11752352, 8665533, 11873706
DRD2 1813 PROMAZINE CHEMBL564 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank 17139284, 17016423
DRD2 1813 DROPERIDOL CHEMBL1108 antagonist TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 2527092, 1549935, 20358234, 14633536
DRD2 1813 ERGOTAMINE CHEMBL442 agonist DrugBank 7665369, 8242725
DRD2 1813 LEVODOPA CHEMBL1009 agonist TdgClinicalTrial, TEND, DrugBank 17553470, 11978145, 9633680, 18549347, 15710490, 15728856, 15824260
DRD2 1813 EDROPHONIUM CHEMBL1104 agonist GuideToPharmacologyInteractions
DRD2 1813 ROTIGOTINE CHEMBL1303 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD 18691132
DRD2 1813 ASENAPINE (CHEMBL3187365) CHEMBL3187365 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
DRD2 1813 BENPERIDOL CHEMBL297302 antagonist GuideToPharmacologyInteractions
DRD2 1813 PIPOTIAZINE CHEMBL398880 antagonist GuideToPharmacologyInteractions, DrugBank 11752352, 11873706, 15694263, 20643630, 16867246, 2875894, 11103886
DRD2 1813 PROCHLORPERAZINE CHEMBL728 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND
DRD2 1813 CHEMBL140184 CHEMBL140184 antagonist GuideToPharmacologyInteractions
DRD2 1813 SCH-23390 CHEMBL62 antagonist GuideToPharmacologyInteractions
DRD2 1813 SERTINDOLE CHEMBL12713 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 18293356, 16925508, 11752352, 20856607, 19506838
DRD2 1813 TRIFLUOPERAZINE CHEMBL422 antagonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND
DRD2 1813 ACEPROMAZINE CHEMBL39560 antagonist DrugBank 11752352, 11873706, 15694263, 20643630, 16867246, 11103886
DRD2 1813 THIOTHIXENE CHEMBL1201 antagonist ChemblInteractions, DrugBank 11752352, 3039860, 11873706, 15694263, 20643630, 16867246, 11103886
DRD2 1813 CHEMBL513521 CHEMBL513521 DrugBank
DRD2 1813 N-DESMETHYLCLOZAPINE CHEMBL845 TdgClinicalTrial, DrugBank
DRD2 1813 BUSPIRONE CHEMBL49 TdgClinicalTrial, TEND
DRD2 1813 BROMOCRIPTINE MESYLATE CHEMBL1200503 agonist ChemblInteractions
DRD2 1813 CHLORPROMAZINE HYDROCHLORIDE CHEMBL1713 antagonist ChemblInteractions
DRD2 1813 QUETIAPINE FUMARATE CHEMBL1200911 antagonist ChemblInteractions
DRD2 1813 PROCHLORPERAZINE EDISYLATE CHEMBL1201154 antagonist ChemblInteractions
DRD2 1813 PARDOPRUNOX CHEMBL2103832 partial agonist, agonist TdgClinicalTrial, ChemblInteractions, TTD
DRD2 1813 METOCLOPRAMIDE HYDROCHLORIDE HYDRATE CHEMBL1200940 antagonist ChemblInteractions
DRD2 1813 MOLINDONE HYDROCHLORIDE CHEMBL1200419 antagonist ChemblInteractions
DRD2 1813 DIHYDROERGOTAMINE CHEMBL1732 agonist TTD
DRD2 1813 ITI-007 (CHEMBL3545044) CHEMBL3545044 partial agonist TdgClinicalTrial, ChemblInteractions
DRD2 1813 BROMPERIDOL CHEMBL28218 PharmGKB
DRD2 1813 CHEMBL3234237 CHEMBL3234237 TdgClinicalTrial
DRD2 1813 PALBOCICLIB CHEMBL189963 antagonist TTD
DRD2 1813 ACETOPHENAZINE MALEATE CHEMBL2360079 antagonist ChemblInteractions
DRD2 1813 ACARBOSE CHEMBL1566 antagonist TTD
DRD2 1813 CHEMBL504548 CHEMBL504548 antagonist TTD
DRD2 1813 AMPHETAMINE CHEMBL405 binder DrugBank 1532675
DRD2 1813 CARIPRAZINE CHEMBL2028019 partial agonist, agonist TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank 23320989
DRD2 1813 HALOPERIDOL CHEMBL54 antagonist, inverse agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, NCI, TEND, TTD 12887421
DRD2 1813 MIANSERIN CHEMBL6437 antagonist DrugBank 2576228
DRD2 1813 BREXPIPRAZOLE CHEMBL2105760 partial agonist, agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 24947465
DRD2 1813 ITOPRIDE CHEMBL2107457 TdgClinicalTrial, DrugBank 17300287, 16495395
DRD2 1813 BROMOPRIDE CHEMBL399510 antagonist DrugBank 14871277
DRD2 1813 ROLICYCLIDINE CHEMBL1719398 DrugBank 19391150
DRD2 1813 BICIFADINE CHEMBL511099 DrugBank 17325229
DRD2 1813 ALCOHOL CHEMBL545 NCI 12749054
DRD2 1813 MORPHINE CHEMBL70 NCI 11943831
DRD2 1813 ANIRACETAM CHEMBL36994 DrugBank 11412837
DRD2 1813 BIFEPRUNOX CHEMBL218166 partial agonist, agonist TdgClinicalTrial, ChemblInteractions, DrugBank, TTD 17659474, 17393144
DRD2 1813 TIAPRIDE CHEMBL84158 blocker DrugBank 11520476
DRD2 1813 LITHIUM CHEMBL2146126 NCI 8787189

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
DRD2 rs1800497 A ethanol dosage yes Adolescents carrying the A allele drank significantly more ethanol over a week than adolescents who did not carry the allele. Please note that alleles have been complemented to the positive strand. Allele A is associated with increased dose of ethanol in children as compared to allele G. 22798433 1450814517
DRD2 rs1800497 AA + AG ethanol dosage no No significant difference in alcohol consumption by adolescents in the AA + AG genotype group compared to GG. Genotypes AA + AG are not associated with dose of ethanol in children as compared to genotype GG. 24134200 1450820618
DRD2 rs4648317 AA methadone "dosage","metabolism/PK" yes Genotype AA is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG. 21902500 827816402
DRD2 rs1800497 A botulinum toxin type a efficacy no No significant difference in allele frequency between responders and non-responders. Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to botulinum toxin type a in women with Migraine NOS as compared to allele G. 31014225 1451104967
DRD2 rs1800497 A venlafaxine efficacy no Generalized anxiety disorder. No significant difference in the number of responders vs non-responders, or remitters vs non-remitters, was seen between any of the genotypes, when considering the Hamilton Anxiety scale (HAM-A) or the Clinical Global Impressions-Improvement scale (CGI-I). After 6 months of treatment, response defined as a HAM-A reduction of >= 50%, remission defined as HAM-A <= 7. On CGI-I scale, response defined as a CGI-I score of 1 and 2, remission defined as a CGI-I score of 1. Allele A is not associated with response to venlafaxine in people with Anxiety Disorders as compared to allele G. 24723432 1184747866
DRD2 rs1799978 T risperidone other yes Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C. 17105675 655387624
DRD2 rs1799732 del clozapine efficacy not stated Allele del is not associated with increased response to clozapine in people with Schizophrenia as compared to allele G. 15830237 637879842
DRD2 rs1799732 G antipsychotics efficacy no No specific antipsychotic is mentioned in the study. Allele G is not associated with response to antipsychotics in people with Schizophrenia as compared to allele del. 9858029 655386544
DRD2 rs6275 A lithium efficacy not stated This is from a review article which does not give all the details. It says that no association was found between the SNP and lithium response, but it does not state exactly how the alleles were compared. Allele A is not associated with response to lithium in people with Bipolar Disorder as compared to allele G. 21047205 699639217
DRD2 rs6275 AA + AG methadone yes Genotypes AA + AG are associated with increased dose of methadone in people with treatment for heroin addiction as compared to genotype GG. 19373123 769169148
DRD2 rs1799732 del antipsychotics efficacy yes in a meta-analysis. Allele del is associated with decreased response to antipsychotics in people with Schizophrenia as compared to genotype GG. 20194480 769168983
DRD2 rs1801028 G olanzapine efficacy no no p-value reported Allele G is not associated with response to olanzapine in people with Schizophrenia as compared to allele C. 19000940 1183689314
DRD2 rs1799732 GG chlorpromazine efficacy yes [stat_test:T1 by CLUMP; 2 d.f.] Ascertained by Improvement on the overall Brief Psychiatry Rating Scale. Genotype GG is associated with increased response to chlorpromazine in people with Schizophrenia as compared to genotypes G/del + del/del. 15694263 769172782
DRD2 rs6277 GG methadone efficacy no Authors stated that an association was found, but that the stated significance level (0.015) should be taken "cautiously" because of the number of SNPs tested. p below was corrected for 5 SNPs tested. [stat_test: chi-square]. Genotype GG is associated with decreased response to methadone in people with Substance-Related Disorders. 18687376 769172931
DRD2 rs6277 GG aripiprazole efficacy yes This was significant for the PANSS excitement subscale - patients with the GG genotype had a higher PANSS excitement score and thus poor response to aripiprazole compared to patients with the AA genotype after 4 weeks of treatment. GA vs AA was not statistically significant (p=0.92 PANSS excitement score). Genotype GG is associated with decreased response to aripiprazole in people with Schizophrenia as compared to genotype AA. 18926547 769250900
DRD2 rs1799732 GG aripiprazole efficacy no No statistically significant effect on PANSS performance was observed with this variant. No individuals had the del/del genotype. Genotype GG is not associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype G/del. 18926547 769250907
DRD2 rs1076560 AA methadone "dosage","metabolism/PK" yes Genotype AA is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC. 21902500 827816415
DRD2 rs1799978 CC methadone "dosage","metabolism/PK" yes Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype TT. 21902500 827816247
DRD2 rs6275 AA methadone "dosage","metabolism/PK" yes Genotype AA is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG. 21902500 827816268
DRD2 rs7131440 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714811
DRD2 rs7122246 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714818
DRD2 rs17601612 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714827
DRD2 rs1801028 GG aripiprazole efficacy no No statistically significant effect on PANSS performance was observed with this variant. Ser311Cys is a C>G change in the DRD2 gene on the minus strand. Here, we show the complement for the plus strand, and so allele C corresponds to Cys and G to Ser alleles. No individuals had the Cys/Cys (CC) genotype. Genotype GG is not associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype CG. 18926547 827832192
DRD2 rs2283265 AA + AC methadone dosage no This association was not statistically significant after permutation analysis based on 40,000 replicates, and not statistically significant after adjusting for testing for multiple SNPs (Bonferroni correction). Note; this association may be linked to the association with rs7118900 in the ANKK1 gene. Alleles were reported as T/G, here they are complemented for the positive chromosomal strand with A representing T and C representing G. Genotypes AA + AC are associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC. 23651024 982032576
DRD2 rs1076560 C venlafaxine efficacy no Generalized anxiety disorder. No significant difference in the number of responders vs non-responders, or remitters vs non-remitters, was seen between any of the genotypes, when considering the Hamilton Anxiety scale (HAM-A) or the Clinical Global Impressions-Improvement scale (CGI-I). After 6 months of treatment, response defined as a HAM-A reduction of >= 50%, remission defined as HAM-A <= 7. On CGI-I scale, response defined as a CGI-I score of 1 and 2, remission defined as a CGI-I score of 1. Allele C is not associated with response to venlafaxine in people with Anxiety Disorders as compared to allele A. 24723432 1184747846
DRD2 rs6277 A methadone dosage no Methadone maintenance dose was not associated with genotype of the SNP but it was correlated to the highest dose ever used. Multiple doses versus single dose, body weight, history of cocaine dependence and ethnicity (Asian>Caucasian>African) were independently associated with methadone dose in multiple regression analysis. Please note: alleles have been complemented to the + strand. Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G. 25556837 1444695435
DRD2 rs1079597 C amisulpride efficacy yes Korean; differences measured after at least 6 weeks treatment; treatment response defined as a reduction of at least 30% from the baseline. Allele C is associated with increased response to amisulpride in people with Schizophrenia as compared to allele T. 25679126 1447676920
DRD2 rs2234689 C Selective serotonin reuptake inhibitors efficacy no Compares association with 3 genotypes and 2 alleles with response and found no association in either case. Allele C is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele G. 25642918 1447679401
DRD2 rs4648318 T heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Please note that alleles have been complemented to the positive strand. Allele T is not associated with response to heroin as compared to allele C. 28692418 1450827353
DRD2 rs1076560 AA + AC olanzapine efficacy yes The associations were evaluated in conjunction with rs6314 in the HTR2A gene. rs1076560 GT/rs6314 CC diplotype was associated with better responses to antipsychotics than the rs1076560 GG/rs6314 CT diplotype Genotypes AA + AC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotype CC. 25563748 1447813735
DRD2 rs2514218 T clozapine efficacy yes as measured by change in brief psychiatric rating scale (BPRS) Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C. 26666695 1447676364
DRD2 rs1799732 del antipsychotics efficacy no Allele is given as del and C. Patients' psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). Drugs prescribed were clozapine (58 patients), risperidone (28 patients), aripiprazole (25 patients), quetiapine (18 patients), olanzapine (12 patients), paliperidone (3 patients), ziprasidone (1 patient), fluphenazine (21 patients), zuclopenthixol (19 patients), amisulpride (13 patients), flupentixol (9 patients), promazine (7 patients), and haloperidol (3 patients). Allele del is not associated with response to antipsychotics in people with Schizophrenia as compared to genotype GG. 27287786 1448258556
DRD2 rs1801028 CG + GG antipsychotics efficacy no Patients' psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). Drugs prescribed were clozapine (58 patients), risperidone (28 patients), aripiprazole (25 patients), quetiapine (18 patients), olanzapine (12 patients), paliperidone (3 patients), ziprasidone (1 patient), fluphenazine (21 patients), zuclopenthixol (19 patients), amisulpride (13 patients), flupentixol (9 patients), promazine (7 patients), and haloperidol (3 patients). Genotypes CG + GG are not associated with response to antipsychotics in people with Schizophrenia as compared to genotype CC. 27287786 1448258550
DRD2 rs2283265 CC rasagiline efficacy yes Efficacy was measured with peak reduction in total UPDRS scores at 12 weeks. Patients were randomly assigned to delayed or early start of rasagiline, at 1 mg or 2 mg daily. Patients with Parkinson's symptoms that progressed were given appropriate therapy and withdrawn from the study. Genotype CC is associated with increased response to rasagiline in people with Parkinson Disease as compared to genotypes AA + AC. 27190009 1447990584
DRD2 rs1076560 CC rasagiline efficacy yes Efficacy was measured with peak reduction in total UPDRS scores at 12 weeks. Patients were randomly assigned to delayed or early start of rasagiline, at 1 mg or 2 mg daily. Patients with Parkinson's symptoms that progressed were given appropriate therapy and withdrawn from the study. Genotype CC is associated with increased response to rasagiline in people with Parkinson Disease as compared to genotypes AA + AC. 27190009 1447990611
DRD2 rs1799732 G/del + del/del nicotine efficacy yes At end of treatment. Not significant at 6 month follow-up (p=0.31). Genotypes G/del + del/del is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG. 16123753 1447960897
DRD2 rs1554929 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714777
DRD2 rs4274224 A opioids dosage no Variant was significantly associated with opioid dose in the development sample, but lost significance in the validation sample. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714097
DRD2 rs6275 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714797
DRD2 rs7131056 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele A. 21398039 1449714836
DRD2 rs6279 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714790
DRD2 rs1125394 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714804
DRD2 rs1800497 AA methadone dosage no Genotype AA is not associated with dose of methadone in people with Substance-Related Disorders as compared to genotypes AG + GG. 18687376 1449271155
DRD2 rs6277 GG methadone dosage no Genotype GG is not associated with dose of methadone in people with Substance-Related Disorders as compared to genotypes AA + AG. 18687376 1449271120
DRD2 rs1800497 AA methadone efficacy no Genotype AA is not associated with response to methadone in people with Substance-Related Disorders as compared to genotypes AG + GG. 18687376 1449271175
DRD2 rs1799978 C methadone efficacy no Response to methadone was measured as the number of urine screens which were positive for opioids during methadone treatment. No participants were found to have the CC genotype. Please note that alleles have been complemented to the positive strand. Allele C is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele T. 26437921 1449164221
DRD2 rs1800497 A buprenorphine efficacy no Alleles are referred to as DRD2 A1 and A2 in the paper. It is assumed that A1 represents the A allele and A2 represents the G allele. Allele A is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to allele G. 16583408 1449161667
DRD2 rs1079597 CT + TT prochlorperazine efficacy yes Patients with the CT or TT genotypes had an increased incidence of nausea when treated with prochlorperazine for opioid-induced nausea and vomiting as compared to patients with the CC genotype. Genotypes CT + TT are associated with decreased response to prochlorperazine in people with Nausea as compared to genotype CC. 24360851 1450820844
DRD2 rs1799978 C risperidone efficacy no Please note that alleles have been complemented to the positive strand. Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T. 28696411 1450928193
DRD2 rs11214607 G heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Allele G is not associated with response to heroin as compared to allele T. 28692418 1450827399
DRD2 rs4436578 C heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Allele C is not associated with response to heroin as compared to allele T. 28692418 1450827348
DRD2 rs1800497 AA + AG nicotine other no Subgroup analysis of schizophrenia patients only found no significant difference in the number of cigarettes smoked per day between the genotype groups. However, the authors noted that female schizophrenia patients with the GG genotype reported smoking significantly more cigarettes per day than male schizophrenia patients carrying the A allele (p=0.28) Genotypes AA + AG are not associated with exposure to nicotine in people with Schizophrenia as compared to genotype GG. 28548579 1450826752
DRD2 rs1079596 T heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Please note that alleles have been complemented to the positive strand. Allele T is not associated with response to heroin as compared to allele C. 28692418 1450827394
DRD2 rs1800497 AA + AG nicotine other no Subgroup analysis of bipolar disorder patients only found no significant difference in number of cigarettes smoked per day between genotype groups. Genotypes AA + AG are not associated with exposure to nicotine in people with Bipolar Disorder as compared to genotype GG. 28548579 1450826746
DRD2 rs2075652 A heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to heroin as compared to allele G. 28692418 1450827343
DRD2 rs1800497 AA + AG venlafaxine efficacy no No significant interaction between this locus and response to venlafaxine treatment for smoking cessation. Genotypes AA + AG are not associated with response to venlafaxine in people with as compared to genotype GG. 15203796 1450808749
DRD2 rs2734833 A heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to heroin as compared to allele G. 28692418 1450827429
DRD2 rs12574471 T heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Allele T is not associated with response to heroin as compared to allele C. 28692418 1450827363
DRD2 rs6277 A nicotine efficacy no Please note that alleles have been complemented to the positive strand. No significant association between this variant and nicotine reward, perception, mood or reinforcement or physiological responses to nicotine. Allele A is not associated with response to nicotine in women as compared to allele G. 18690117 1450812289
DRD2 rs2514218 CC aripiprazole efficacy yes Patients with the CC genotype had a greater reduction in symptoms over 12 weeks of treatment with either aripiprazole or risperidone. Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT. 26320194 1450823635
DRD2 rs1800497 AA + AG nicotine other no Analysis of the total cohort found no significant difference in number of cigarettes smoked per day between genotype groups. Genotypes AA + AG are not associated with exposure to nicotine in people with Bipolar Disorder or Schizophrenia as compared to genotype GG. 28548579 1450826739
DRD2 rs1800497 A risperidone efficacy no Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to risperidone in people with Schizophrenia as compared to allele G. 28696411 1450928201
DRD2 rs1079597 T prochlorperazine efficacy no No significant difference in incidence of vomiting between genotype groups when treated with prochlorperazine for opioid-induced nausea and vomiting. Allele T is not associated with response to prochlorperazine in people with Vomiting as compared to allele C. 24360851 1450820850
DRD2 rs7131056 A heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Allele A is not associated with response to heroin as compared to allele C. 28692418 1450827379
DRD2 rs1799978 TT risperidone efficacy yes Patients with the TT genotype had better improvement in total PANSS score than patients with the CT genotype. Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype CT. 18855532 655387634
DRD2 rs4936274 A heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. The authors note that this variant was not in Hardy-Weinberg equilibrium in the study cohort. Allele A is not associated with response to heroin as compared to allele G. 28692418 1450827454
DRD2 rs4648317 A opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Please note that alleles have been complemented to the positive strand. Allele A is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714843
DRD2 rs7131056 A Selective serotonin reuptake inhibitors efficacy no Compares association with 3 genotypes and 2 alleles with response and found no association in either case. Allele A is not associated with response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to allele C. 25642918 1447679388
DRD2 rs6277 A heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Please note that alleles have been complemented to the positive strand. Allele A is not associated with response to heroin as compared to allele G. 28692418 1450827419
DRD2 rs6277 A nicotine efficacy yes Please note that alleles have been complemented to the positive strand. Male subjects with the AA genotype had a higher perception score of "feel the effects" of nicotine with 5ug/kg nicotine, while male subjects with the AA or AG genotypes had higher "feel the effects" scores with 10ug/kg. Male subjects with the AA genotype had decreased fatigue and increased anger in the mood scoring compared to male subjects with the AG or GG genotypes. There was no significant association between this variant and physiological responses to nicotine, performance task responses or nicotine reinforcement. Allele A is associated with increased response to nicotine in men as compared to allele G. 18690117 1450812316
DRD2 rs1076560 A heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Allele A is not associated with response to heroin as compared to allele C. 28692418 1450827389
DRD2 rs1799732 del clozapine efficacy not stated Allele del is not associated with increased response to clozapine in people with Schizophrenia as compared to allele G. 9918131 637879832
DRD2 rs1799732 del risperidone no Allele del is not associated with response to risperidone in people with Schizophrenia. 17105675 655387630
DRD2 rs1799732 GG bupropion efficacy yes At end of treatment. Not significant at 6 month follow-up (p=0.08). Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes G/del + del/del. 16123753 1447960889
DRD2 rs1799732 G/del aripiprazole efficacy not stated A 51 y.o African-American man with schizoaffective disorder, depressive and post-traumatic stress disorder was referred to a community mental health center to address medication non-adherence and lack of medication effectiveness. The patient began treatment with long-acting injectable (LAI) aripiprazole (400 mg) every 4-weeks plus 30 mg/day of oral aripiprazole, which was reduced to 15 mg/day 2-weeks post-injection. 8 weeks later psychiatric symptoms improved and over 12-weeks, dose was reduced to 5 mg/day. Within 4-weeks of this dosing strategy, auditory hallucinations returned and worsened. Oral aripiprazole dose increased to 7.5 mg/day with improvement in sypmptoms but at 2-week and 3 week follow-ups auditory hallucinations returned so aripiprazole LAI frequency increased to every 3-weeks (and 7.5 mg/day oral). Pharmacogenetic testing revealed the patient to carry the rs1799732 (-141C/ Del) variant (without complement to the + chromosomal strand) and he was switched to 882 mg/3 weeks of injectable aripiprazole lauroxil without oral aripiprazole in December of 2015 and as of February 2017 continues to tolerate the aripiprazole lauroxil and reports not needing oral aripiprazole. Genotype G/del is associated with decreased response to aripiprazole in people with schizoaffective disorder. 28673279 1449140243